Results 101 to 110 of about 41,253 (155)

Differences in COVID-19-related hospitalization burden between kidney transplant recipients and hemodialysis patients vaccinated against COVID-19. [PDF]

Hum Vaccin Immunother
Fernández-Chávez AC, Ordoñez-León GY, Mendoza-Gómez MY, Sánchez-Carmona DL, Aranaz-Andrés JM.   +4 more
europepmc   +1 more source

An adenovirus-vectored recombinant vaccine confers passive immunity protection from swine acute diarrhea syndrome coronavirus challenge in neonatal mice. [PDF]

Virol Sin
Zhang Y, Duan Y, Zhu X, Shi L, Zhang J, Mao W, Li L, Yuan C, Sun M, Zheng H, Wang Q.   +10 more
europepmc   +1 more source

Advances in the prevention of respiratory syncytial virus infection in children. [PDF]

J Bras Pneumol
Krey JG, Manfroi L, Damian FB, Pinto LA, Scotta MC.   +4 more
europepmc   +1 more source

Evaluation of the Safety and Efficacy of the Respiratory Syncytial Virus FG Chimeric Vaccine KD-409 in Rodent Models for Maternal and Pediatric Vaccination. [PDF]

Vaccines (Basel)
Yamaue R, Terashima M, Soejima K, Torikai M.   +3 more
europepmc   +1 more source

Antibodies against polysaccharide type 3 and pneumococcal proteins demonstrate synergistic protective effect in a highly virulent type 3 invasive disease model in mice. [PDF]

Front Immunol
Stevenson TC, Burke H, Roggensack SE, Pratt A, Hossain A, Ghosh P, Besin G, Lu Y, Zhang F, Malley R, Sebastian S.   +10 more
europepmc   +1 more source

Understanding the impact of Klebsiella pneumoniae K-Antigen based MAPS vaccine design on the immune response in animal models. [PDF]

PLoS Pathog
Palmieri E, Belciug GF, Nonne F, Massai L, Valensin S, De Rosa A, Berlanda Scorza F, Rondini S, Carducci M, Rossi O, Micoli F, Giannelli C.   +11 more
europepmc   +1 more source

Passive immunity.

Actualidad medica, 2010
openaire   +1 more source

Insights and challenges on animal models for progressive multiple sclerosis. [PDF]

J Neuroinflammation
Nalepa IF, Haahr NO, Bekiaris V, Jakobsen MR, Asuni AA, Benmamar-Badel A.   +5 more
europepmc   +1 more source

Comparative Analysis of Reported Adverse Events with Nirsevimab and Palivizumab: A FAERS Observational Study. [PDF]

Kans J Med
Touffaha I, Ablah E, Okut H, Homan G.
europepmc   +1 more source